Picture of Devonian Health logo

GSD Devonian Health Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+4.43%
3m+28.23%
6m+51.62%
1yr+21.61%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-25.42%
50d MA+25.36%
200d MA-30.41%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-32.25%
Return on Equity-30.22%
Operating Margin-85.08%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Jul 202431st Jul 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Devonian Health EPS forecast chart

Profile Summary

Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis.

Directors

    Last Annual
    July 31st, 2023
    Last Interim
    January 31st, 2024
    Incorporated
    May 12th, 2017
    Public Since
    September 9th, 2014
    No. of Employees
    6
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    ca flag iconTSX Venture Exchange
    Shares in Issue
    148,222,531

    GSD Share Price Performance

    Upcoming Events for GSD

    Q3 2024 Devonian Health Group Inc Earnings Release

    Similar to GSD

    Picture of Aequus Pharmaceuticals logo

    Aequus Pharmaceuticals

    ca flag iconTSX Venture Exchange

    Picture of Avricore Health logo

    Avricore Health

    ca flag iconTSX Venture Exchange

    Picture of Biosyent logo

    Biosyent

    ca flag iconTSX Venture Exchange

    Picture of Cytophage Technologies logo

    Cytophage Technologies

    ca flag iconTSX Venture Exchange

    Picture of Decibel Cannabis logo

    Decibel Cannabis

    ca flag iconTSX Venture Exchange

    FAQ